PMID- 19900154
OWN - NLM
STAT- MEDLINE
DCOM- 20100304
LR  - 20171116
IS  - 1557-8518 (Electronic)
IS  - 1540-4196 (Linking)
VI  - 7
IP  - 6
DP  - 2009 Dec
TI  - The effect of exercise on serum levels of interleukin-18 and components of the 
      metabolic syndrome.
PG  - 579-84
LID - 10.1089/met.2009.0003 [doi]
AB  - BACKGROUND: There is increasing evidence that the metabolic syndrome is 
      associated with a proinflammatory state. Interleukin-18 (IL-18) has been shown to 
      be associated with multiple components of the syndrome and to predict the 
      development of diabetes and cardiovascular events. The aim of the present work 
      was to investigate if exercise could reduce serum levels of IL-18 in subjects 
      with the metabolic syndrome, and if potential changes would be associated with 
      changes in body composition and components of the syndrome. Pravastatin was used 
      for comparison. METHODS: We investigated the effect of 12 weeks of intervention 
      with exercise, pravastatin, or both on serum levels of IL-18 in 34 subjects with 
      the metabolic syndrome. RESULTS: Levels of IL-18 were reduced by exercise (P = 
      0.036), pravastatin (P = 0.036), and the combination (P = 0.017) versus baseline, 
      however without intergroup differences. Still, the reduction in the exercise 
      group was not negligible (17.5%). Furthermore, reduced levels of IL-18 were 
      significantly associated with improvement of an increasing number of components 
      of the metabolic syndrome (P = 0.034). This effect is likely to be caused by 
      exercise, because this intervention had a beneficial effect on components of the 
      syndrome compared to the control group (P = 0.029). CONCLUSIONS: Our findings 
      suggest that the protective effect of exercise might be due in part to reduced 
      inflammation associated with improvement of the metabolic syndrome and its 
      components. Studies with larger sample sizes are warranted to confirm this 
      hypothesis.
FAU - Troseid, Marius
AU  - Troseid M
AD  - Center for Clinical Heart Research, Department of Cardiology, Oslo University 
      Hospital, Ulleval, Oslo, Norway. troseid@hotmail.com
FAU - Lappegard, Knut T
AU  - Lappegard KT
FAU - Mollnes, Tom E
AU  - Mollnes TE
FAU - Arnesen, Harald
AU  - Arnesen H
FAU - Seljeflot, Ingebjorg
AU  - Seljeflot I
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Metab Syndr Relat Disord
JT  - Metabolic syndrome and related disorders
JID - 101150318
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-18)
RN  - KXO2KT9N0G (Pravastatin)
SB  - IM
MH  - Adult
MH  - Cardiovascular Diseases/prevention & control
MH  - Combined Modality Therapy
MH  - *Exercise Therapy
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Inflammation Mediators/blood
MH  - Interleukin-18/*blood
MH  - Male
MH  - Metabolic Syndrome/*blood/drug therapy/*therapy
MH  - Middle Aged
MH  - Pravastatin/therapeutic use
EDAT- 2009/11/11 06:00
MHDA- 2010/03/05 06:00
CRDT- 2009/11/11 06:00
PHST- 2009/11/11 06:00 [entrez]
PHST- 2009/11/11 06:00 [pubmed]
PHST- 2010/03/05 06:00 [medline]
AID - 10.1089/met.2009.0003 [doi]
PST - ppublish
SO  - Metab Syndr Relat Disord. 2009 Dec;7(6):579-84. doi: 10.1089/met.2009.0003.